



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

OSIMERTinib (Tagrisso™)



* O S I - 0 0 0 0 0 - D L - C N - T X *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Advanced stage EGFR mutation positive lung adenocarcinoma:

First-line therapy.

Subsequent-line therapy after failure or intolerance to first/second generation anti-EGFR.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
OSIMERTinib	80 mg PO daily	To be given with or without food. If a dose is missed, Don't make up the missed dose, take the next dose as scheduled.
To be given continuously until disease progression or intolerable toxicity.		

Special instructions:

- Avoid concomitant use with strong CYP3A4 inducers (Anticonvulsants).
- If coadministration with a strong CYP3A4 inducer cannot be avoided, increase OSIMERTinib dose to 160 mg once daily.
- Reduce OSIMERTinib dose to 80 mg once daily 3 weeks after discontinuation of the strong CYP3A4 inducer.

Treatment Description:

Cycle	Date	OSIMERTinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No